Review





Similar Products

94
Cytoskeleton Inc aac01 rrid ab 2533450 anti rabbit trimethyllysine ptm bio
Aac01 Rrid Ab 2533450 Anti Rabbit Trimethyllysine Ptm Bio, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/Actin+Binding+Protein+Spin-Down+Assay+Biochem+Kit/pm42684891-458-84-82
Average 94 stars, based on 1 article reviews
aac01 rrid ab 2533450 anti rabbit trimethyllysine ptm bio - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology rabbit anti tata binding protein tbp ab
Rabbit Anti Tata Binding Protein Tbp Ab, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/TBP+Antibody/pm41290870-197-41-47
Average 94 stars, based on 1 article reviews
rabbit anti tata binding protein tbp ab - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

86
Glaxo Smith treatment ab 10 52 binding summary
Treatment Ab 10 52 Binding Summary, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/10+52+ab+binding+summary+treatment/sec_filing____726512_slash_000101287003001216_slash_d10k-1308-8-19
Average 86 stars, based on 1 article reviews
treatment ab 10 52 binding summary - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc 9601s rrid ab 330306
9601s Rrid Ab 330306, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/Phospho-(Ser)+14-3-3+Binding+Motif+Antibody/pmc12648754-730-6-2
Average 94 stars, based on 1 article reviews
9601s rrid ab 330306 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

90
Molecular Dynamics Inc fireball ab initio tight-binding molecular-dynamics formalism
Fireball Ab Initio Tight Binding Molecular Dynamics Formalism, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/tight+binding+molecular+dynamics/pmc11247479__jz4c00164_si_001-160-6-11
Average 90 stars, based on 1 article reviews
fireball ab initio tight-binding molecular-dynamics formalism - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Green Mountain Antibodies anti-hfviii binding ab green mountain antibodies #gma8016
a Mean with SEM of <t>hFVIII</t> concentration in the plasma of immune tolerant hemophilia A mice, treated with (red squares) or without (black squares) anti-IFNAR1 Ab (50 mg/kg, i.v.) or with a control Ab (immunoglobulin G control, IgG control, pink squares) 3 h before LV-FVIII (4–7 × 10 10 TU/kg). Pool of two independent experiments. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FVIII control group, performed at the last time-point. b Single values and mean with SEM of VCN measured in the indicated fractionated or FACS-sorted liver cell types of mice in ( a ) 5 months post-LV. Two-tailed Mann-Whitney test. c Mean with SEM of hFIX concentration in the plasma of WT mice, treated with Bortezomib (1 mg/kg, blue dots) and/or Anti-IFNAR1 Ab (50 mg/kg, purple or red dots, as indicated) or saline (black dots), 1 h or 3 h before LV-FIX (2.75 × 10 10 TU/kg). Two-tailed linear-mixed effects (LME) model (for complete analyses see Supplementary Table ) over LV-FIX group. d Single values and mean with SEM of VCN measured in fractionated and FACS-sorted liver cell types of mice in ( c ) 3 months post-LV. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FIX control group. e Single values and mean with SEM of the percentage of GFP-positive hepatocytes (7 fields/sample) transduced with PGK.GFP LV (multiplicity of infection (MOI): 2), in the presence (blue triangles) or absence (black triangles) of Bortezomib (100 nM) at the time of transduction, and analyzed 7 days after transduction. As a control for inhibition of GFP degradation, Bortezomib (100 nM) was added 2 days after LV administration (condition Bort control, gray triangles). f Single values and mean with SEM of VCN measured in the above-described experiment. Kruskal-Wallis test with Dunn’s multiple comparisons test. Source data are provided as a Source Data file.
Anti Hfviii Binding Ab Green Mountain Antibodies #Gma8016, supplied by Green Mountain Antibodies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/anti+hfviii+binding+ab+green+mountain+antibodies++gma8016/pmc12102377-433-5-8
Average 90 stars, based on 1 article reviews
anti-hfviii binding ab green mountain antibodies #gma8016 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
AbMax Inc ab binding
a Mean with SEM of <t>hFVIII</t> concentration in the plasma of immune tolerant hemophilia A mice, treated with (red squares) or without (black squares) anti-IFNAR1 Ab (50 mg/kg, i.v.) or with a control Ab (immunoglobulin G control, IgG control, pink squares) 3 h before LV-FVIII (4–7 × 10 10 TU/kg). Pool of two independent experiments. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FVIII control group, performed at the last time-point. b Single values and mean with SEM of VCN measured in the indicated fractionated or FACS-sorted liver cell types of mice in ( a ) 5 months post-LV. Two-tailed Mann-Whitney test. c Mean with SEM of hFIX concentration in the plasma of WT mice, treated with Bortezomib (1 mg/kg, blue dots) and/or Anti-IFNAR1 Ab (50 mg/kg, purple or red dots, as indicated) or saline (black dots), 1 h or 3 h before LV-FIX (2.75 × 10 10 TU/kg). Two-tailed linear-mixed effects (LME) model (for complete analyses see Supplementary Table ) over LV-FIX group. d Single values and mean with SEM of VCN measured in fractionated and FACS-sorted liver cell types of mice in ( c ) 3 months post-LV. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FIX control group. e Single values and mean with SEM of the percentage of GFP-positive hepatocytes (7 fields/sample) transduced with PGK.GFP LV (multiplicity of infection (MOI): 2), in the presence (blue triangles) or absence (black triangles) of Bortezomib (100 nM) at the time of transduction, and analyzed 7 days after transduction. As a control for inhibition of GFP degradation, Bortezomib (100 nM) was added 2 days after LV administration (condition Bort control, gray triangles). f Single values and mean with SEM of VCN measured in the above-described experiment. Kruskal-Wallis test with Dunn’s multiple comparisons test. Source data are provided as a Source Data file.
Ab Binding, supplied by AbMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/ab+binding/pm40332355-190-1-9
Average 90 stars, based on 1 article reviews
ab binding - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Thermo Fisher human fc receptor binding inhibitor ab
a Mean with SEM of <t>hFVIII</t> concentration in the plasma of immune tolerant hemophilia A mice, treated with (red squares) or without (black squares) anti-IFNAR1 Ab (50 mg/kg, i.v.) or with a control Ab (immunoglobulin G control, IgG control, pink squares) 3 h before LV-FVIII (4–7 × 10 10 TU/kg). Pool of two independent experiments. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FVIII control group, performed at the last time-point. b Single values and mean with SEM of VCN measured in the indicated fractionated or FACS-sorted liver cell types of mice in ( a ) 5 months post-LV. Two-tailed Mann-Whitney test. c Mean with SEM of hFIX concentration in the plasma of WT mice, treated with Bortezomib (1 mg/kg, blue dots) and/or Anti-IFNAR1 Ab (50 mg/kg, purple or red dots, as indicated) or saline (black dots), 1 h or 3 h before LV-FIX (2.75 × 10 10 TU/kg). Two-tailed linear-mixed effects (LME) model (for complete analyses see Supplementary Table ) over LV-FIX group. d Single values and mean with SEM of VCN measured in fractionated and FACS-sorted liver cell types of mice in ( c ) 3 months post-LV. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FIX control group. e Single values and mean with SEM of the percentage of GFP-positive hepatocytes (7 fields/sample) transduced with PGK.GFP LV (multiplicity of infection (MOI): 2), in the presence (blue triangles) or absence (black triangles) of Bortezomib (100 nM) at the time of transduction, and analyzed 7 days after transduction. As a control for inhibition of GFP degradation, Bortezomib (100 nM) was added 2 days after LV administration (condition Bort control, gray triangles). f Single values and mean with SEM of VCN measured in the above-described experiment. Kruskal-Wallis test with Dunn’s multiple comparisons test. Source data are provided as a Source Data file.
Human Fc Receptor Binding Inhibitor Ab, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab+binding+%26+washing+buffer/human+fc+receptor+binding+inhibitor/pmc12191616-198-16-22
Average 90 stars, based on 1 article reviews
human fc receptor binding inhibitor ab - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


a Mean with SEM of hFVIII concentration in the plasma of immune tolerant hemophilia A mice, treated with (red squares) or without (black squares) anti-IFNAR1 Ab (50 mg/kg, i.v.) or with a control Ab (immunoglobulin G control, IgG control, pink squares) 3 h before LV-FVIII (4–7 × 10 10 TU/kg). Pool of two independent experiments. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FVIII control group, performed at the last time-point. b Single values and mean with SEM of VCN measured in the indicated fractionated or FACS-sorted liver cell types of mice in ( a ) 5 months post-LV. Two-tailed Mann-Whitney test. c Mean with SEM of hFIX concentration in the plasma of WT mice, treated with Bortezomib (1 mg/kg, blue dots) and/or Anti-IFNAR1 Ab (50 mg/kg, purple or red dots, as indicated) or saline (black dots), 1 h or 3 h before LV-FIX (2.75 × 10 10 TU/kg). Two-tailed linear-mixed effects (LME) model (for complete analyses see Supplementary Table ) over LV-FIX group. d Single values and mean with SEM of VCN measured in fractionated and FACS-sorted liver cell types of mice in ( c ) 3 months post-LV. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FIX control group. e Single values and mean with SEM of the percentage of GFP-positive hepatocytes (7 fields/sample) transduced with PGK.GFP LV (multiplicity of infection (MOI): 2), in the presence (blue triangles) or absence (black triangles) of Bortezomib (100 nM) at the time of transduction, and analyzed 7 days after transduction. As a control for inhibition of GFP degradation, Bortezomib (100 nM) was added 2 days after LV administration (condition Bort control, gray triangles). f Single values and mean with SEM of VCN measured in the above-described experiment. Kruskal-Wallis test with Dunn’s multiple comparisons test. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes

doi: 10.1038/s41467-025-60073-0

Figure Lengend Snippet: a Mean with SEM of hFVIII concentration in the plasma of immune tolerant hemophilia A mice, treated with (red squares) or without (black squares) anti-IFNAR1 Ab (50 mg/kg, i.v.) or with a control Ab (immunoglobulin G control, IgG control, pink squares) 3 h before LV-FVIII (4–7 × 10 10 TU/kg). Pool of two independent experiments. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FVIII control group, performed at the last time-point. b Single values and mean with SEM of VCN measured in the indicated fractionated or FACS-sorted liver cell types of mice in ( a ) 5 months post-LV. Two-tailed Mann-Whitney test. c Mean with SEM of hFIX concentration in the plasma of WT mice, treated with Bortezomib (1 mg/kg, blue dots) and/or Anti-IFNAR1 Ab (50 mg/kg, purple or red dots, as indicated) or saline (black dots), 1 h or 3 h before LV-FIX (2.75 × 10 10 TU/kg). Two-tailed linear-mixed effects (LME) model (for complete analyses see Supplementary Table ) over LV-FIX group. d Single values and mean with SEM of VCN measured in fractionated and FACS-sorted liver cell types of mice in ( c ) 3 months post-LV. Kruskal-Wallis test with Dunn’s multiple comparisons test over LV-FIX control group. e Single values and mean with SEM of the percentage of GFP-positive hepatocytes (7 fields/sample) transduced with PGK.GFP LV (multiplicity of infection (MOI): 2), in the presence (blue triangles) or absence (black triangles) of Bortezomib (100 nM) at the time of transduction, and analyzed 7 days after transduction. As a control for inhibition of GFP degradation, Bortezomib (100 nM) was added 2 days after LV administration (condition Bort control, gray triangles). f Single values and mean with SEM of VCN measured in the above-described experiment. Kruskal-Wallis test with Dunn’s multiple comparisons test. Source data are provided as a Source Data file.

Article Snippet: Microtiter plates were coated with anti-hFVIII binding Ab (Green Mountain Antibodies #GMA8016, 0.2 μg/well in 0.1 M carbonate buffer, pH 9.6) overnight at 4 °C and then blocked for 1 h at room temperature with blocking buffer (PBS 0.05% Tween-20, 1 M NaCl, 10% heat-inactivated horse serum, Gibco).

Techniques: Concentration Assay, Clinical Proteomics, Control, Two Tailed Test, MANN-WHITNEY, Saline, Transduction, Infection, Inhibition